New weapon tested against stubborn blood cancers
NCT ID NCT05362773
Summary
This is the first study in people testing a new drug called MGD024 for several types of blood cancers that have come back or stopped responding to standard treatments. The main goal is to find a safe dose and understand how the drug works in the body. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Colorado Blood Cancer Network
RECRUITINGDenver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Duke University Medical Center
COMPLETEDDurham, North Carolina, 27710, United States
-
START - Midwest
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
South Austin Medical Center
RECRUITINGAustin, Texas, 78704, United States
-
University of Maryland, Greenbaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.